| Premature senescence is a major response to DNA cross-linking agents in BRCA1-defective cells: implication for tailored treatments of BRCA1 mutation carriers. | |
| | |
MedLine Citation:
|
PMID: 19372557 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BRCA1-associated tumors are characterized by an elevated genomic instability and peculiar expression profiles. Nevertheless, tailored treatments for BRCA1 mutation carriers have only been partially investigated up to now. The implementation of therapeutic strategies specific for these patients has been in part hindered by the paucity of proper preneoplastic and neoplastic BRCA1-deficient tumor cell models. In this study, we took advantage of the RNA interference technology to generate a series of partially transformed (HBL100) and tumorigenic (MCF7 and T47D) breast cancer cell lines in which BRCA1 expression was silenced at different levels. These cell models were probed by clonogenic assay for their response to several DNA-damaging agents commonly used in cancer therapy (mitomycin C, cisplatin, doxorubicin, and etoposide). Our models confirmed the peculiar sensitivity to interstrand cross-link inducers associated with BRCA1 deficiency. Intriguingly, the increased sensitivity to these compounds displayed by BRCA1-defective cells was not correlated with the extent of apoptotic cell death but rather associated to an increased fraction of growth-arrested, enlarged, multinucleated beta-galactosidase-positive senescent cells. Overall, our results support a role for BRCA1 in the regulation of interstrand cross-link-induced premature senescence and suggest a reconsideration of the therapeutic power of mitomycin/platinum-based treatments in BRCA1 carriers. Moreover, our data further prompt the setup of strategies for the imaging of the senescence response in vivo. |
| | |
Authors:
|
Manuela Santarosa; Laura Del Col; Elena Tonin; Angela Caragnano; Alessandra Viel; Roberta Maestro |
Related Documents
:
|
8240377 - Expression of receptors for advanced glycosylation end products on renal cell carcinoma... 8671637 - Stage-specific alterations in murine b lymphopoiesis with age. 8368137 - Genetic and molecular basis for cellular senescence. 1245297 - Contact inhibition of pleiotropin pinocytosis as a critical factor in metazoan cell age... 7585587 - Relaxin activates the l-arginine-nitric oxide pathway in human breast cancer cells. 3780107 - Choroid plexus and ependymal cells in csf cytology. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Molecular cancer therapeutics Volume: 8 ISSN: 1535-7163 ISO Abbreviation: Mol. Cancer Ther. Publication Date: 2009 Apr |
Date Detail:
|
Created Date: 2009-04-17 Completed Date: 2009-06-08 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101132535 Medline TA: Mol Cancer Ther Country: United States |
Other Details:
|
Languages: eng Pagination: 844-54 Citation Subset: IM |
Affiliation:
|
Experimental Oncology 1, Centro di Riferimento Oncologico, Istituto Di Ricovero e Cura a Carattere Scientifico, National Cancer Institute, via F. Gallini 2, Aviano 33081 PN, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aging, Premature
/
physiopathology* Antibiotics, Antineoplastic / pharmacology Antineoplastic Agents, Phytogenic / pharmacology Apoptosis / drug effects BRCA1 Protein / genetics*, metabolism Breast Neoplasms / drug therapy*, genetics*, metabolism Cell Aging / drug effects* Cell Line, Transformed / drug effects Cells, Cultured Cisplatin / pharmacology* Colony-Forming Units Assay Cross-Linking Reagents / pharmacology* Doxorubicin / pharmacology Etoposide / pharmacology Humans Mitomycin / pharmacology |
| Chemical | |
Reg. No./Substance:
|
0/Antibiotics, Antineoplastic; 0/Antineoplastic Agents, Phytogenic; 0/BRCA1 Protein; 0/Cross-Linking Reagents; 15663-27-1/Cisplatin; 23214-92-8/Doxorubicin; 33419-42-0/Etoposide; 50-07-7/Mitomycin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colore...
Next Document: Ataxia telangiectasia and rad3-related kinase contributes to cell cycle arrest and survival after ci...